ArticlePsychopharmacology2026
Xylazine exacerbates fentanyl-induced respiratory depression and prevents rescue by naloxone in mice.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cannabinoid CBBritish journal of pharmacology · 2026Article
- Reinforcing effects of fentanyl/xylazine mixtures in monkeys responding under a food-versus-drug choice procedure.Behavioural pharmacology · 2026Article
Corrections and comments
- Update of
Authors and funding
4 authors.
Funding
Abstract
introductionXylazine is a veterinary sedative and widespread adulterant of illicit opioids, where it is commonly detected in combination with the potent synthetic µ opioid receptor (MOR) agonist fentanyl in fatal overdose.
methodsWe used whole body plethysmography to evaluate the respiratory effects of xylazine in the presence and absence of fentanyl in awake C57BL/6 mice of both sexes. We asked whether suppression of breathing by xylazine-adulterated fentanyl resisted reversal with naloxone. We identified receptor mechanisms necessary to reverse effects of xylazine-adulterated fentanyl on breathing.
resultsXylazine rapidly and dose-dependently suppressed minute ventilation, respiratory frequency, and tidal volume, producing profound respiratory depression at low doses. These effects were dependent on α-2 adrenergic receptors (α2ARs) and were blocked by the α2AR antagonist atipamezole. Xylazine, combined with a dose of fentanyl with modest respiratory effects, suppressed breathing with greater efficacy than when administered alone. A dose of naloxone sufficient to reverse fentanyl-induced respiratory depression was ineffective in reversing the respiratory suppression induced by xylazine-adulterated fentanyl. By contrast, combinations of naloxone with atipamezole rapidly and fully reversed respiratory suppression induced by xylazine-adulterated fentanyl. The same dose of atipamezole, administered alone, produced significant, but markedly delayed reversal.
conclusionXylazine suppresses breathing via activation of α2ARs, an effect enhanced by coadministration with the MOR agonist fentanyl. Respiratory suppression inflicted by the mixture of xylazine and fentanyl resisted reversal by naloxone but was fully reversible by subsequent coadministration of both naloxone and atipamezole.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.